相关实验视频

Updated: Jun 3, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

评估较大的侧组功能和Ritonavir等CYP3A4抑制剂的侧组/终组相互作用

Eric R Samuels¹, Irina F Sevrioukova²

¹Department of Pharmaceutical Sciences, University of California, Irvine, California, USA.

Chemical biology & drug design

|January 10, 2025

概括

研究人员设计了类似于利托纳维尔的新型CYP3A4抑制剂,以探索侧组相互作用. 化合物中含有甲和,显示出强烈的结合和抑制,突显了特定结构配置在药物发现中的重要性.

科学领域:

药用化学医学化学
药物发现药物发现药物发现
酶抑制可以抑制酶.

背景情况:

细胞染色体P450 3A4 (CYP3A4) 是一种关键的药物代谢酶.
利托纳维尔是一种众所周知的CYP3A4抑制剂.
了解抑制剂的结构-活性关系对于开发新疗法至关重要.

研究的目的:

设计和合成针对人类CYP3A4.4的新型利托纳维尔类抑制剂.
调查R2侧组和R3末组修饰对抑制活性之间的相互作用.
通过合理的药物设计来识别强大的CYP3A4抑制剂.

主要方法:

合理的药物设计 13 种与里托纳维尔类似的化合物.
抑制剂的光谱,功能和结构特征.
结合亲和力 (Ks) 和抑制功效 (IC50) 的测定.

主要成果:

R3-Boc组的延长或化并没有改善抑制剂的性能.
将R2从基替换为英多尔或纳夫他林,并将R3作为皮里丁,产生了多样化的结果.
这种R2-甲烯/R3-二烯化合物2f (R/S) 成为一种强大的抑制剂 (Ks = 0.009 μM,IC50 = 0.10 μM).
较大的R2组,如双和,没有改善;含的化合物13是最弱的抑制剂.
观察到R2-双和R3-Boc的合规重组,受小末端组的影响.

结论:

R2和R3组的相互作用显著影响CYP3A4的抑制.
特定的结构特征,如R2的纳夫他林和R3的胺,对于高结合亲和力和强度至关重要.
结构洞察对于预测和优化抑制剂疗效至关重要,特别是关于形状灵活性.

关键词:

在 CYP3A4 中.晶体结构晶体结构设计抑制剂的设计抑制剂抑制复杂的抑制复杂的里托纳维尔的类似物结构活动关系结构活动关系

更多相关视频

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...

Dose-Response Relationship: Potency and Efficacy

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...